CYTOKINETICS INC (CYTK) Form 8-K — Aug 6, 2026

Key figures

Revenue

$28.6 million

Guidance

FY2026 GAAP combined R&D and SG&A expense raised to $860 million-$890 million (from $830 million-$870 million), including $130 million-$140 million non-cash stock-based compensation

Net Income

-$198.8 million net loss, basic and diluted (vs -$134.4 million, or $(1.12) per share, in Q2 2025)

Total Debt

$1.15 billion (term loan $248.2 million, convertible notes $871.5 million, current portion of convertible and long-term debt $27.4 million)

Revenue Yoy

down from $66.8 million in Q2 2025; decline driven by absence of $64.4 million in license and milestone revenue recorded in the prior-year quarter vs none in Q2 2026

Total Assets

$1.92 billion

Cash Position

$1.7 billion in cash, cash equivalents and investments as of June 30, 2026

Offering Price

71

Shares Offered

11338028

Snda timing

Q4 2026 for aficamten in non-obstructive HCM

Rnd expense q2

$97.8 million vs $110.1 million in Q2 2025

Sga expense q2

$104.4 million vs $65.7 million in Q2 2025

Six month revenue

$48.0 million

Cash prior quarter

$1.1 billion at March 31, 2026

Patients dispensed

approximately 1,500

Product revenue q2

$25.3 million MYQORZO net product revenue ($23.0 million US, $2.3 million Europe)

Six month net loss

$404.8 million ($(3.17) per share)

Unique prescribers

over 700

Stockholders deficit

-$173.5 million

Offering net proceeds

$760.1 million

Paid prescription share

over 80%

Collaboration revenue q2

$3.3 million vs $2.4 million in Q2 2025

Revenue participation liabilities

~$694.5 million ($558.1 million RPI purchase agreements + $136.4 million RPI fair value)

Price after filing

Close on the filing date to close N calendar days later (from $78.61). Historical, not a forecast.